Rebecca Taub sold $10M of MDGL
Pres., R&D, and CMO at MADRIGAL PHARMACEUTICALS, INC.. 18,650 shares at an average of $552.15, traded Dec 10, 2025, filed Dec 12, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.3M at market
- 0Share of holdings soldSold 3.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.0%, 3m -22.2%, 6m -15.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-056792, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | MOption exercise Common Stock10b5-1 | +18,650 | $15.80 | $295k | 479,694 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -491 | $547.76 | $269k | 479,203 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -369 | $548.56 | $202k | 478,834 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -486 | $550.07 | $267k | 478,348 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -4,723 | $550.99 | $2.6M | 473,625 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -4,410 | $551.85 | $2.4M | 469,215 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -3,857 | $552.81 | $2.1M | 465,358 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -3,087 | $553.88 | $1.7M | 462,271 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -1,027 | $554.84 | $570k | 461,244 | Dec 12, 2025 |
| Dec 10, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $555.39 | $111k | 461,044 | Dec 12, 2025 |
| Dec 10, 2025 | GGift Common Stock10b5-1 | -5,455 | $0.00 | $0 | 455,589 | Dec 12, 2025 |
| Dec 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,650 | $0.00 | $0 | 18,650 | Dec 12, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.